Squarepoint
SPRY icon

Squarepoint’s ARS Pharmaceuticals SPRY Stock Holding History

Squarepoint’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Sell
24,904
-89,369
-78% -$769K ﹤0.01% 4069
2026
Q1 		$918K Buy
+114,273
New +$1.1M ﹤0.01% 2839
2025
Q4 		– Sell
-35,856
Closed -$360K – 4857
2025
Q3 		$360K Buy
+35,856
New +$515K ﹤0.01% 3523
2025
Q2 		– Sell
-76,824
Closed -$966K – 5019
2025
Q1 		$966K Buy
76,824
+52,047
+210% +$626K ﹤0.01% 2699
2024
Q4 		$261K Sell
24,777
-9,204
-27% -$129K ﹤0.01% 4256
2024
Q3 		$493K Buy
+33,981
New +$404K ﹤0.01% 3108
2023
Q3 		– Sell
-84,808
Closed -$568K – 4216
2023
Q2 		$568K Buy
84,808
+71,905
+557% +$480K ﹤0.01% 2547
2023
Q1 		$84K Buy
+12,903
New +$99.1K ﹤0.01% 3002
2021
Q4 		– Sell
-15,593
Closed -$156K – 3498
2021
Q3 		$156K Buy
15,593
+6,492
+71% +$160K ﹤0.01% 2581
2021
Q2 		$281K Buy
+9,101
New +$292K ﹤0.01% 2587

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Squarepoint's SPRY Position: Q2 2026 in Review

Squarepoint reduced its ARS Pharmaceuticals (SPRY) stake by 78% in Q2 2026, selling an estimated $769K and leaving 24,904 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #4069.

Squarepoint first reported a position in SPRY in Q2 2021 and has held it in 10 quarters since. The position peaked at $966K in Q1 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Squarepoint held 24,904 shares of ARS Pharmaceuticals worth $199K as of Q2 2026.
  • Squarepoint sold 89,369 ARS Pharmaceuticals shares in Q2 2026, an estimated $769K.
  • ARS Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4069 holding.
  • Squarepoint first reported a position in ARS Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
  • Squarepoint's ARS Pharmaceuticals position peaked at $966K in Q1 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.